Clinical trials: psoriasis
Scalp Psoriasis
To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis
This is a phase III, randomized, double-blind, placebo-controlled, parallel- group, multiple-site study to evaluate the therapeutic equivalence of generic calcipotriene and betamethasone dipropionate topical suspension…
- Trial name
- NCT03331523
- Testing
- Calcipotriene/Betamethasone Dipropionate, Taclonex®
- Where
- 31 sites in United States
- Volunteers
- 643 people
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Psoriatic Arthritis
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).
- Trial name
- NCT06671496
- Testing
- Zasocitinib
- Where
- 120 sites in United States, Argentina and 10 more
- Volunteers
- 601 people
- Sponsor
- Takeda
Chronic Plaque Psoriasis
Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis
Loading dose, four arm, double-blind, parallel group, placebo-controlled study comparing single and multiple doses of AIN457 to placebo in patients with a diagnosis of moderate to severe chronic plaque psoriasis.
- Trial name
- NCT00805480
- Testing
- AIN457
- Volunteers
- 130 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)
The purpose of the study is to evaluate the ability of subjects with moderate to severe chronic plaque psoriasis (PSO) to safely and effectively self-inject bimekizumab at study start and 8 weeks after training in self-injection…
- Trial name
- NCT03766685
- Testing
- Bimekizumab
- Where
- 39 sites in United States, Canada
- Volunteers
- 172 people
- Sponsor
- UCB Biopharma SRL
Plaque Psoriasis
A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis
To compare disease activity, as measured by PASI score, of three MEDI-507 dosing (injection)regimens vs. placebo.
- Trial name
- NCT00540618
- Testing
- MEDI-507
- Where
- 43 sites in United States, Canada
- Volunteers
- 420 people
- Sponsor
- MedImmune LLC
Psoriatic Arthritis
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
The main purpose of this study is to evaluate the safety and long-term efficacy of ixekizumab compared to placebo in participants with active psoriatic arthritis.
- Trial name
- SPIRIT P3 (NCT02584855)
- Testing
- Ixekizumab
- Where
- 106 sites in United States, Bulgaria and 10 more
- Volunteers
- 394 people
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis
RESTORE: Raptiva® (Efalizumab) Evaluation of Safety and Treatment Optimization
RESTORE is an observational, open-label, multi-center, prospective, study enrolling Raptiva® (efalizumab) treated patients with moderate to severe chronic plaque psoriasis.
- Trial name
- RESTORE (NCT00402818)
- Where
- Canada
- Volunteers
- 294 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Psoriasis Vulgaris
The Efficacy Of A Dead Sea Mineral Enriched Body Cream vs Its Carrier as an Adjuvant Treatment For Psoriatic Patients
This is a two-center study aimed to assess the efficacy of Dead Sea Minerals in alleviating symptoms of Psoriasis Vulgaris, in 50 patients undergoing phototherapy.
- Trial name
- NCT01651559
- Where
- 2 sites in Israel
- Volunteers
- 50 people
- Sponsor
- Ahava Dead Sea Laboratories
Chronic Plaque-type Psoriasis
Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab
The aim of this study was to describe the effect of direct IL-17A inhibition with secukinumab as compared with the selective inhibition of IL-23 with guselkumab (p19 subunit blocker) in controlling inflammation in psoriatic…
- Trial name
- ARROW (NCT03553823)
- Testing
- Skin biopsies
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis
To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis
This study is a phase 3 study,to evaluate the efficacy and safety of different doses of JAK1 inhibitor SHR0302 in subjects with active psoriatic arthritis.
- Trial name
- NCT04957550
- Where
- China
- Volunteers
- 418 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Plaque Psoriasis
A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy
This is a double-blind, placebo-controlled study in adults with a diagnosis of moderate-to-severe chronic plaque psoriasis to test the efficacy and safety of piclidenoson in this patient population.
- Trial name
- NCT06643260
- Testing
- piclidenoson
- Volunteers
- 705 people
- Sponsor
- Can-Fite BioPharma
Nail Psoriasis, Plaque Psoriasis
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
This study is being conducted to assess the safety and efficacy of adalimumab in participants with nail psoriasis.
- Trial name
- NCT02016482
- Testing
- Adalimumab
- Volunteers
- 217 people
- Sponsor
- AbbVie
Rheumatoid Arthritis (RA), Atopic Dermatitis (AD)
A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints characterized by the swelling of multiple joints and tenderness caused by progressive inflammatory synovitis, which leads to serious and debilitating diseases.
- Conditions
- Rheumatoid Arthritis (RA), Atopic Dermatitis (AD), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA)
- Trial name
- NCT04541810
- Where
- 116 sites in South Korea
- Volunteers
- 2,369 people
- Sponsor
- AbbVie
Generalized Pustular Psoriasis, Erythrodermic Psoriasis
A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis
The reason for this study is to see if the study drug ixekizumab is safe and effective in participants with generalized pustular psoriasis and erythrodermic psoriasis.
- Trial name
- NCT03942042
- Testing
- Ixekizumab
- Where
- 7 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis
Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis
To compare the safety and efficacy of Padagis' product to an FDA approved product for the treatment of plaque psoriasis
- Trial name
- NCT05763082
- Testing
- roflumilast cream 0.3%, Zoryve
- Where
- United States
- Volunteers
- 416 people
- Sponsor
- Padagis LLC
Rheumatoid Arthritis, Arthritis, Psoriatic
Golimumab Safety and Surveillance Program Using the Ingenix NHI Database
The participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan.The objective of this study is to…
- Conditions
- Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing Spondylitis
- Trial name
- NCT01081717
- Testing
- systemic non-biological treatments, anti-TNF biologics, golimumab
- Volunteers
- 1,064 people
- Sponsor
- Janssen Biotech, Inc.
Plaque Psoriasis
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the potential of DFD01 spray to suppress the HPA (hypothalamic-pituitary-adrenal) axis as compared to Comp01 lotion when applied twice daily for 15 days.
- Trial name
- BDS1307 (NCT02070965)
- Testing
- DFD01 Spray, Comp01 Lotion
- Where
- 12 sites in United States
- Volunteers
- 75 people
- Sponsor
- Primus Pharmaceuticals
Plaque Psoriasis
A Study to Evaluate ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis
This randomized, double-blinded dose-finding study evaluates four dose levels of ABY-035, in comparison to placebo, in subjects with moderate to severe plaque psoriasis.
- Trial name
- AFFIRM-35 (NCT03591887)
- Testing
- ABY-035
- Where
- 18 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Affibody
Psoriatic Arthritis
A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis
This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical study, consisting of a 4-week screening period, a 24-week core treatment period, a 24-week maintenance treatment period, and an 8-week…
- Trial name
- NCT06640257
- Testing
- SHR-1314 injection
- Where
- China
- Volunteers
- 208 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Psoriasis
KX01 Ointment Phase 1 Study in Patients With Plaque Type Psoriasis
This is a Phase I dose escalation study to assess the safety, tolerability and activity of three different strengths of topical KX01 in the treatment of patients with plaque-type psoriasis.
- Trial name
- NCT05522816
- Testing
- KX01 0.01% (0.1 mg/g), KX01 0.1% (1.0 mg/g), KX01 1% (10 mg/g) for 5 days
- Volunteers
- 28 people
- Sponsor
- PharmaEssentia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.